68Ga-PSMA PET/CT评估177Lu-PSMA-617放射配体治疗mCRPC疗效
该回顾性研究纳入48例接受177Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌(mCRPC)患者,比较治疗前与第三或第四周期后68Ga-PSMA PET/CT按改良PERCIST标准评估的疗效与PSA下降≥50%参考标准。PET/CT灵敏度约85%、特异度55%–65%,ROC曲线下面积0.70,应答者与无应答者生存期差异无统计学意义。
要点
- 68Ga-PSMA PET/CT评估177Lu-PSMA-617疗效灵敏度约85%,特异度55%–65%。
- PET/CT阴性及阳性预测值介于70%–78%,ROC曲线下面积0.70。
- PET应答者生存期约19.6个月,无应答者约15.9个月,差异无统计学意义。
核心结论
- 68Ga-PSMA PET/CT可能是在诊疗一体化框架下评估177Lu-PSMA-617放射配体治疗疗效的有用工具。
研究设计与样本
- 回顾性研究纳入德国波恩大学医院和亚琛大学医院48例接受177Lu-PSMA-617治疗的mCRPC患者,均有首次治疗前及第三或第四周期后的68Ga-PSMA PET/CT影像。
- 以PSA下降≥50%为参考标准,按改良PERCIST标准定义基于68Ga-PSMA PET/CT的治疗应答。
主要发现
- 68Ga-PSMA PET/CT评估治疗应答的灵敏度约85%,特异度介于55%–65%。
- 阴性预测值和阳性预测值介于70%–78%,拟合ROC曲线下面积为0.70。
- 治疗应答者生存期约19.6个月,无应答者约15.9个月,但组间差异无统计学意义。
关键数值与推荐
- 治疗应答基于改良版PERCIST标准由68Ga-PSMA PET/CT判定。
- 参考标准为PSA水平下降≥50%。
临床怎么用
- 在诊疗一体化框架下,可考虑用68Ga-PSMA PET/CT监测177Lu-PSMA-617治疗应答,但需结合PSA等指标综合判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the use of 68Ga-PSMA PET/CT for monitoring response to 177Lu-617 PSMA radioligand therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC). METHODS: Patients from the University Hospital Bonn and the University Hospital Aachen were retrospectively reviewed for this study. We included 48 patients with mCRPC who were treated with 177Lu-PSMA-617 and whose records included 68Ga-PSMA PET/CT imaging before the first and after the third or fourth treatment cycle. A treatment response based on 68Ga-PSMA PET/CT was defined according to a modified version of the PERCIST criteria. A decline in PSA level of ≥50% was considered the reference standard. The sensitivity, specificity, positive and negative predictive values, and ROC curves were calculated, and patient survival times in relation to the PET results were also analysed. RESULTS: 68Ga-PSMA PET/CT had a sensitivity of about 85% and a specificity of between 55% and 65%. The negative and positive predictive values ranged between 70% and 78%. The fitted ROC area was 0.70. The survival time was about 19.6 months in patients with a treatment response, while nonresponders had a survival time of about 15.9 months. However, this difference between the groups was not statistically significant. CONCLUSION: Our results indicate that 68Ga-PSMA PET/CT could be a useful tool for the evaluation of response to 177Lu-PSMA-617 radioligand therapy within a theranostic framework.
引用
- Heinzel A, Boghos D, Mottaghy FM, et al. 68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019. PMID: 30697649. doi:10.1007/s00259-019-4258-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。